Mark Appleby

Mark Appleby serves as the VP of Preclinical Research at Implicit Bioscience, leading initiatives focused on neurodegenerative disease since 2016. Previous experience includes tenures at Novo Nordisk Research Center as a Principal Scientist in both the Diabetic Complications and AutoImmune Disease Research Groups, contributing to corporate strategy and target discovery until the latter therapeutic area was discontinued. Earlier roles encompass senior scientist positions at ZymoGenetics and Celltech, where Mark directed discovery and validation programs, established state-of-the-art programs in immune function research, and collaborated on external partnerships. Mark’s academic credentials include a PhD in Cellular Pathology from the University of Cambridge and a Research Fellowship in Immunology at the University of Washington.